Singapore, Nov. 11 -- The Health Sciences Authority received information related to the study titled 'Anti-CD7 Protein Expression Blocker (PEBL) Chimeric-Antigen Receptor (CAR) T-Cell Therapy for Relapsed/ Refractory T-Lineage Acute Lymphoblastic Leukaemia (CARTALL-2): A Phase 2 study'. The following are the other relevant details related to the trial:
Therapeutic Area: Oncology (including Haematology-Oncology)
Trial Centre(s):
National University Hospital
Trial Status: NA
Principal Investigator(s):
Dr Allen Yeoh Eng Juh
Published by HT Digital Content Services with permission from Health Daily Digest....